Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): A randomised, double-blind, phase 2 study

The Lancet Oncology

Volumn 17, Issue 2, 2016, Pages 153-163

  Shore, Neal D ^a   Chowdhury, Simon ^b   Villers, Arnauld ^c   Klotz, Laurence ^d   Robert Siemens, D ^e   Phung, De ^f   van Os, Steve ^f   Hasabou, Nahla ^g   Wang, Fong ^h   Bhattacharya, Suman ^h   Heidenreich, Axel ⁱ  

^a Carolina Urologic Research Center   (United States)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c UNIV LILLE   (France)

^d UNIVERSITY OF TORONTO   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f Astellas Pharma Global Development   (Netherlands)

^g ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^h Medivation Inc   (United States)

ⁱ RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; ENZALUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ANILIDE; NITRILE; PHENYLTHIOHYDANTOIN; TOLUENESULFONIC ACID DERIVATIVE;

ADULT; AGED; ANEMIA; ANTIANDROGEN THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; BONE PAIN; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EUROPE; FATIGUE; FOLLOW UP; FRACTURE; HEART INFARCTION; HOT FLUSH; HUMAN; HYDRONEPHROSIS; HYPERTENSION; INTERACTIVE VOICE RESPONSE SYSTEM; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; METASTATIC PROSTATE CANCER; MULTICENTER STUDY; NAUSEA; NORTH AMERICA; OPEN STUDY; ORCHIECTOMY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; HEART FAILURE; MIDDLE AGED; PATHOLOGIC FRACTURE; PATIENT DROPOUT; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; ANILIDES; ARTHRALGIA; BACK PAIN; CONSTIPATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DYSPNEA; FATIGUE; FRACTURES, SPONTANEOUS; HEART FAILURE; HOT FLASHES; HUMANS; HYDRONEPHROSIS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NAUSEA; NITRILES; PATIENT DROPOUTS; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TOSYL COMPOUNDS;

EID: 84959368921     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00518-5     Document Type: Article

References (23)

1. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014, 65:467-479.
2. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014, 371:424-433.
3. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368:138-148.
4. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008, 68:4447-4454.
5. Grossmann ME, Huang H, Tindall DJ Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001, 93:1687-1697.
6. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10:33-39.
7. Knudsen KE, Scher HI Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009, 15:4792-4798.
8. Knudsen KE, Kelly WK Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab 2011, 6:483-493.
9. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011, 59:572-583.
10. Saad F, Chi KN, Finelli A, et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2015, 9:90-96.
11. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014, 32:3436-3448.
12. Kucuk O, Fisher E, Moinpour CM, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001, 58:53-58.
13. Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Urol Int 2005, 75:217-221.
14. Paul R, Breul J Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Drug Saf 2000, 23:381-390.
15. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
16. von Klot CA, Kuczyk MA, Merseburger AS No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. Eur Urol 2014, 65:258-259.
17. Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, et al. Is there an anti-androgen withdrawal syndrome with enzalutamide?. BJU Int 2015, 115:373-380.
18. Jung ME, Ouk S, Yoo D, et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 2010, 53:2779-2796.
19. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
20. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
22. Kolvenbag GJ, Blackledge GR, Gotting-Smith K Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate 1998, 34:61-72.
23. Penson D, Armstrong AJ, Concepcion R, et al. A multicenter phase 2 study of enzalutamide (ENZA) versus bicalutamide (BIC) in men with nonmetastatic (M0) or metastatic (M1) castration-resistant prostate cancer (CRPC): the STRIVE Trial. J Urol 2015, 193:e499.